The Soluble Urokinase-Type Plasminogen Activator Receptor As a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 23

PMID 34680247

Citations 4

Authors

Kristian Blomberg

Torben F Hansen

Claus L Brasen

Jeppe B Madsen

Lars H Jensen

Caroline B Thomsen

Affiliations

Soon will be listed here.

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10-2.92, = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings.

Citing Articles

suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma.

Azawi N, Mosholt K, Fryd N, Lund L, Brignone J, Hvid N BMC Urol. 2023; 23(1):168.

PMID: 37875832 PMC: 10594785. DOI: 10.1186/s12894-023-01337-z.

Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.

Carmi Y, Khamaisi H, Adawi R, Noyman E, Gopas J, Mahajna J Int J Mol Sci. 2023; 24(9).

PMID: 37175439 PMC: 10178190. DOI: 10.3390/ijms24097730.

Assessment of clinical utility and predictive potential of pre-chemotherapy soluble urokinase plasminogen activator receptor: Observational single center study.

Beleva E, Stoencheva S, Deneva T, Nenova I, Grudeva-Popova Z Biomol Biomed. 2022; 23(2):287-297.

PMID: 36124441 PMC: 10113945. DOI: 10.17305/bjbms.2022.7857.

Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Alfano D, Franco P, Stoppelli M Front Cell Dev Biol. 2022; 10:818616.

PMID: 35493073 PMC: 9045800. DOI: 10.3389/fcell.2022.818616.

References

Riisbro R, Christensen I, Nielsen H, Brunner N, Nilbert M, Fernebro E . Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2017; 20(2):93-102. DOI: 10.5301/JBM.2008.5473. View

van der Geest L, Lam-Boer J, Koopman M, Verhoef C, Elferink M, de Wilt J . Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015; 32(5):457-65. DOI: 10.1007/s10585-015-9719-0. View

Baker E, Bergin F, Leaper D . Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol. 2001; 53(6):307-12. PMC: 1186985. DOI: 10.1136/mp.53.6.307. View

Hamie L, Daoud G, Nemer G, Nammour T, El Chediak A, Uthman I . SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgrad Med J. 2018; 94(1115):517-524. DOI: 10.1136/postgradmedj-2018-135839. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View

Laerum O, Ovrebo K, Skarstein A, Christensen I, Alpizar-Alpizar W, Helgeland L . Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer. 2011; 131(3):558-69. DOI: 10.1002/ijc.26382. View

Buo L, Meling G, Karlsrud T, Johansen H, Aasen A . Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol. 1995; 26(10):1133-8. DOI: 10.1016/0046-8177(95)90276-7. View

Hartmann Rasmussen L, Schultz M, Gaardsting A, Ladelund S, Garred P, Iversen K . Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. Int J Cancer. 2017; 141(1):191-199. PMC: 5518177. DOI: 10.1002/ijc.30732. View

Dohn L, Pappot H, Iversen B, Illemann M, Hoyer-Hansen G, Christensen I . uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications. PLoS One. 2015; 10(8):e0135824. PMC: 4546385. DOI: 10.1371/journal.pone.0135824. View

10.

Tarpgaard L, Christensen I, Hoyer-Hansen G, Lund I, Guren T, Glimelius B . Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. Int J Cancer. 2015; 137(10):2470-7. DOI: 10.1002/ijc.29476. View

11.

Skovsted T, Petersen E, Fruekilde M, Pedersen A, Pielak T, Eugen-Olsen J . Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA. Scand J Clin Lab Invest. 2020; 80(4):327-335. DOI: 10.1080/00365513.2020.1741674. View

12.

Velissaris D, Zareifopoulos N, Koniari I, Karamouzos V, Bousis D, Gerakaris A . Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease. J Clin Med Res. 2021; 13(3):133-142. PMC: 8016523. DOI: 10.14740/jocmr4459. View

13.

Altman D, Royston P . The cost of dichotomising continuous variables. BMJ. 2006; 332(7549):1080. PMC: 1458573. DOI: 10.1136/bmj.332.7549.1080. View

14.

Illemann M, Laerum O, Hasselby J, Thurison T, Hoyer-Hansen G, Nielsen H . Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med. 2014; 3(4):855-64. PMC: 4303153. DOI: 10.1002/cam4.242. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I . Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum Pathol. 2009; 41(1):70-8. DOI: 10.1016/j.humpath.2009.05.013. View

17.

Stephens R, Nielsen H, Christensen I, Thorlacius-Ussing O, Sorensen S, Dano K . Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999; 91(10):869-74. DOI: 10.1093/jnci/91.10.869. View

18.

Vasbinder A, Raffield L, Gao Y, Engstrom G, Quyyumi A, Reiner A . Assay-related differences in SuPAR levels: implications for measurement and data interpretation. J Nephrol. 2022; 36(1):157-159. PMC: 9106999. DOI: 10.1007/s40620-022-01344-7. View

19.

Seetoo D, Crowe P, Russell P, Yang J . Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol. 2003; 82(3):184-93. DOI: 10.1002/jso.10210. View

20.

Lomholt A, Hoyer-Hansen G, Nielsen H, Christensen I . Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer. 2009; 101(6):992-7. PMC: 2743369. DOI: 10.1038/sj.bjc.6605228. View